<DOC>
	<DOCNO>NCT01629745</DOCNO>
	<brief_summary>RATIONALE : Testing minimal residual disease blood sample patient acute lymphoblastic leukemia may help doctor plan good treatment . PURPOSE : This research trial study genetic test detect minimal residual disease sample young patient register COG-AALL08B1 trial .</brief_summary>
	<brief_title>Genetic Test Detecting Minimal Residual Disease Samples From Younger Patients Registered COG-AALL08B1 Trial</brief_title>
	<detailed_description>OBJECTIVES : - Assess feasibility minimal residual disease ( MRD ) determination pediatric B-lineage acute lymphoblastic leukemia ( ALL ) use deep sequencing immunoglobulin heavy chain locus . OUTLINE : Archived blood tumor tissue sample analyze MDR use deep sequencing immunoglobulin heavy chain locus . MDR quantification result compare flow cytometry reference method use COG study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Immunoglobulin Heavy Chains</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Samples patient register Children Oncology Group ( COG ) AALL08B1 protocol store Hematopathology Laboratory University Washington Pretreatment induction therapy sample PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
</DOC>